All Oncology News

Patients with MCL who received real-world brexu-cel experienced lower survival when they were BTK inhibitor refractory and/or had lower platelet counts.

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.

Apalutamide reduced the risk of death by over 20% vs enzalutamide and abiraterone acetate, respectively, in metastatic castration-sensitive prostate cancer.

The EC approved glofitamab with gemcitabine/oxaliplatin for patients with relapsed or refractory diffuse large B-cell lymphoma, ineligible for ASCT.

The FDA granted fast track designation to emactuzumab for unresectable tenosynovial giant cell tumor.

Maurie Markman, MD, discusses the potential to shift the focus of cancer research towards the "real high technology of medicine", such as cancer vaccines.

K. “Vish” Viswanath, PhD, of Dana-Farber Cancer Center, has been named Fellow of the American Association for the Advancement of Science.

Pamela T. Soliman, MD, MPH, discusses a phase 1 investigation of temsirolimus plus metformin in patients with recurrent endometrial cancer.

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

PROs and gene expression in peripheral blood varied in patients with acute myeloid leukemia receiving induction chemotherapy.

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Cancer clinical trial education is valuable and may promote current and future participation.

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

Tarlatamab improved overall survival vs chemotherapy in small cell lung cancer following progression on or after platinum-based chemotherapy.

Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.

The FDA has awarded full approval to frontline nivolumab plus ipilimumab for the treatment of adult patients with unresectable hepatocellular carcinoma.

A phase 1 trial demonstrated that AFM13-NK cells are safe and highly effective in heavily pretreated patients with lymphomas.

Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.

Social factors including financial needs and stress caused increased levels of psychoneurological symptoms in breast cancer survivors.

A clinical trial steering committee from the Mount Sinai Health System helped integrate therapeutic clinical trials into the SOC for patients with cancer.

Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.